Theranos raises $28.5M for device tracking effects of drugs on patients
Theranos, a Menlo Park company developing devices that enable healthcare professionals and pharmaceutical companies to track patients’ responses to drugs, has raised $28.5 million of a $30 million planned third round, according to a filing with the Securities and Exchange Commission cited by VentureWire (sub required).
ATA Ventures, Tako Ventures, Draper Fisher Jurvetson and Continental Properties Inc. were listed as investors in the Form D filing received by the SEC on Nov. 17.
The company raised more than $10 million in a second round in March, and an undisclosed amount in 2004, according to the report.
Next Story: Atrua raises $9 million for mobile phone finger recognition technology
Previous Story: VistaGen announces plans to raise up to $20M for Parkinson's drug, but is it legal?
